Patents Assigned to WARSZAWSKI UNIWERSYTET MEDYCZNY
-
Patent number: 11029314Abstract: A method for diagnosis of IgA nephropathy is provided using a combination of alpha-1B-glycoprotein (A1BG) or a truncated fragment thereof having a molecular weight of 13-60 kDa, orosomucoid 1 (ORMI), and Ig lambda-2 chain C regions (IGLC2) as protein markers in a urine sample from a subject.Type: GrantFiled: June 12, 2017Date of Patent: June 8, 2021Assignees: INSTYTUT BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK, WARSZAWSKI UNIWERSYTET MEDYCZNYInventors: Krzysztof Mucha, Leszek Paczek, Radoslaw Zagozdzon, Bartosz Foroncewicz, Michal Dadlez, Magdalena Bakun, Jan Piwowarski, Tomas Pilzys, Michal Marcinkowski, Damian Garbicz, Elzbieta Grzesiuk, Michal Florczak
-
Patent number: 10702633Abstract: The method, characterized in that, the powdered chitosan is dissolved in water to obtain a 5% solution, into which a 70-90% acetic acid is added and after the formation of the blank intramedullary nail and carrying a coagulating bath and neutralization bath it is subjected to a crosslinking bath in a solution formed from 0.5 to 2% of sodium tri-polyphosphate and 0.5% to 3% Na3PO4 for 24 to 48 hours in temperature of 50° C. to 140° C. and then it is subjected to the drying process, for a period of 6 to 10 days, and finally the surface of the blank is treated to form the intramedullary nail. The surface treatment is carried out until the surface of the intramedullary nail contains at least 20%-40% of the pore of the depth of 0.1 mm to 1 mm.Type: GrantFiled: June 26, 2017Date of Patent: July 7, 2020Assignee: WARSZAWSKI UNIWERSYTET MEDYCZNYInventors: Tomasz Ciach, Jaroslaw Deszczyński, Jaroslaw Michal Deszczyński, Tomasz Mitek, Lukasz Nagraba, Artur Stolarczyk
-
Patent number: 10370404Abstract: Described herein is compound including a protoescigenin derivative having pharmacological properties. Also described are a process of its preparation, and the use of such a compound as a medicament, especially for treating vascular disorders. A pharmaceutical composition comprising such compound is further described.Type: GrantFiled: February 26, 2016Date of Patent: August 6, 2019Assignee: Warszawski Uniwersytet MedycznyInventors: Katarzyna Koziak, Krzysztof Bojakowski, Magdalena Kowalewska, Dorota Maciejko, Oliwia Zegrocka-Stendel, Iwona Grabowska, Grzegorz Grynkiewicz, Mariusz Marek Gruza, Kamil Jatczak, Katarzyna Filip, Piotr Cmoch, Marta Laszcz, Malgorzata Dutkiewicz
-
Patent number: 9850467Abstract: We disclose the use of a strain of bacteriophages in the manufacturing of a preparation for improving the state of health of patients infected with adenoviruses, wherein preferably the preparation produced is used for the treatment or prevention of adenoviral infections, particularly those caused by HAdV, preferably HAdV-5.Type: GrantFiled: June 3, 2014Date of Patent: December 26, 2017Assignees: Warszawski Uniwersytet Medyczny, Instytut Immunologii i Terapii Doswiadczalnej im. Ludwika Hirszfelda PAN we WroclawiuInventors: Renata Jakubowska-Zahorska, Maciej Przybylski, Jan Borysowski, Andrzej Gorski, Beata Weber-Dabrowska
-
Patent number: 9682056Abstract: A description and explanation is provided of the use of oleacein, especially this obtained from Ligustrum vulgare L., in the manufacturing of a preparation for the treatment and prevention of diseases that are consequences of the atherosclerotic plaque degradation. Such diseases include in particular those selected from the following group: ischemic brain stroke, heart attack and ischemic heart disease.Type: GrantFiled: July 13, 2013Date of Patent: June 20, 2017Assignee: Warszawski Uniwersytet MedycznyInventors: Monika Ewa Czerwinska, Anna Karolina Kiss, Marek Aleksy Naruszewicz, Agnieszka Filipek
-
Publication number: 20170151040Abstract: Disclosed herein is a ring prepared from osteoinductive and/or osteogenic material for a use in a dental and orthognathic surgery in case of bone surface deficiency for the introduction of intraosseous dental implants.Type: ApplicationFiled: July 15, 2015Publication date: June 1, 2017Applicant: WARSZAWSKI UNIWERSYTET MEDYCZNYInventors: Piotr Wychowanski, Anna Chroscicka, Malgorzata Lewandowska-Szumiel, Ilona Kalaszczynska
-
Publication number: 20160122725Abstract: We disclose the use of a strain of bacteriophages in the manufacturing of a preparation for improving the state of health of patients infected with adenoviruses, wherein preferably the preparation produced is used for the treatment or prevention of adenoviral infections, particularly those caused by HAdV, preferably HAdV-5.Type: ApplicationFiled: June 3, 2014Publication date: May 5, 2016Applicants: Warszawski Uniwersytet Medyczny, Instytut Immunologii I Terapii Doswiadczalnej im. Ludwika Hirszfelda PAN we WroclawiuInventors: Renata Jakubowska-Zahorska, Maciej Przybylski, Jan Borysowski, Andrzej Gorski, Beata Weber-Dabrowska
-
Publication number: 20160008311Abstract: A description and explanation is provided of the use of oleacein, especially this obtained from Ligustrum vulgare L., in the manufacturing of a preparation for the treatment and prevention of diseases that are consequences of the atherosclerotic plaque degradation. Such diseases include in particular those selected from the following group: ischemic brain stroke, heart attack and ischemic heart disease.Type: ApplicationFiled: July 13, 2013Publication date: January 14, 2016Applicant: Warszawski Uniwersytet MedycznyInventors: Monika Ewa Czerwinska, Anna Karolina Kiss, Marek Aleksy Naruszewicz, Agnieszka Filipek
-
Patent number: 9101577Abstract: The disclosed analgesic pharmaceutical composition for oral administration is characterized in that it contains an opioid and a pharmaceutically admissible magnesium (II) compound, possibly along with one or more pharmaceutically admissible ancillary substances.Type: GrantFiled: May 31, 2012Date of Patent: August 11, 2015Assignee: Warszawski Uniwersytet MedycznyInventors: Magdalena Bujalska-Zadrozny, Marek Naruszewicz
-
Patent number: 9073813Abstract: A process for the preparation of protoescigenin by hydrolysis of escin isolated from Aesculus hippocastanum. The process includes the following steps: a two-step hydrolysis first under acidic and then basic conditions, enrichment of the crude mixture of sapogenins with protoescigenin, an isolation of the mixture of sapogenins in a solid form, and a purification of the obtained solid and isolation of high purity protoescigenin. The invention also relates to protoescigenin monohydrate in a crystalline form and the preparation thereof. Protoescigenin is a polyhydroxy aglycone, which can be used as a synthon in the chemical modifications of naturally occurring saponins.Type: GrantFiled: January 3, 2013Date of Patent: July 7, 2015Assignees: INSTYTUT FARMACEUTYCZNY, WARSZAWSKI UNIWERSYTET MEDYCZNYInventors: Mariusz Gruza, Oliwia Zegrocka-Stendel, Tomasz Giller, Grzegorz Grynkiewicz, Marta Laszcz, Kamil Jatczak
-
Patent number: 9018255Abstract: The subject of the present invention are novel esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them and their use in the production of drugs for the prophylaxis or treatment of oncogenic diseases and diseases connected with increased cell proliferation.Type: GrantFiled: October 16, 2011Date of Patent: April 28, 2015Assignees: Instytut Chemii Organicznej Polskiej Akademii Nauk, Warszawski Uniwersytet MedycznyInventors: Ryszard Ostaszewski, Szymon Klossowski, Izabela Ziuzia, Angelika Szokalska, Marta Swiech, Jakub Golab
-
Publication number: 20140127302Abstract: The disclosed analgesic pharmaceutical composition for oral administration is characterised in that it contains an opioid and a pharmaceutically admissible magnesium (II) compound, possibly along with one or more pharmaceutically admissible ancillary substances.Type: ApplicationFiled: May 31, 2012Publication date: May 8, 2014Applicant: Warszawski Uniwersytet MedycznyInventors: Magdalena Bujalska-Zadrozny, Marek Naruszewicz
-
Publication number: 20130190538Abstract: A process for the preparation of protoescigenin by hydrolysis of escin isolated from Aesculus hippocastanum. The process includes the following steps: a two-step hydrolysis first under acidic and then basic conditions, enrichment of the crude mixture of sapogenins with protoescigenin, an isolation of the mixture of sapogenins in a solid form, and a purification of the obtained solid and isolation of high purity protoescigenin. The invention also relates to protoescigenin monohydrate in a crystalline form and the preparation thereof. Protoescigenin is a polyhydroxy aglycone, which can be used as a synthon in the chemical modifications of naturally occurring saponins.Type: ApplicationFiled: January 3, 2013Publication date: July 25, 2013Applicants: WARSZAWSKI UNIWERSYTET MEDYCZNY, INSTYTUT FARMACEUTYCZNYInventors: INSTYTUT FARMACEUTYCZNY, WARSZAWSKI UNIWERSYTET MEDYCZNY